NewGenIvf Group Limited NIVF PHARMA
Company Overview
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing. It also offers IVF treatment; surrogacy and ancillary caring services, and value-added services comprising nutrition guidance, psychological counselling, acupuncture, and translation interpreters to supplement the IVF treatment. The company provides its services through clinics. NewGenIvf Group Limited was founded in 2010 and is based in Bangkok, Thailand.
Why Investors Should Care
Generates a return on equity of 79.4%, reflecting efficient use of shareholder capital.
Net profit has compounded at 178.2% per year over the last five years.
Carries low leverage with a debt-to-equity ratio of 0.19.
Recent Developments
- Dec 2025 Revenue of $4.73M (-13.0% YoY); net profit $9.88M.
- Trailing 12 Months Year-on-year growth — revenue +11.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -7.4%, profit CAGR 178.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -7.36% |
| 1 Year: | 11.90% |
Compounded Profit Growth
| 5 Years: | 178.23% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -99.68% |
| 6 Months: | -94.10% |
| 3 Months: | -77.37% |
| 1 Month: | -41.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.17 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 79.4%.
- Profit CAGR of 178.2% over 5 years.
CONS
- Revenue declined at -7.4% CAGR over 5 years.
- Trading 99.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NIVF NewGenIvf Group Limited PHARMA | 1.11 | 0.00 | $7.07M | 0.00% | -35.34% | 79.40% | -7.36% | 178.23% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Sep 2025 | Dec 2025 |
|---|---|---|---|
| Revenue | 1.27M | 1.28M | 1.42M |
| Cost of Revenue | 734.48K | 1.16M | 900.53K |
| Gross Profit | 539.13K | 118.02K | 524.02K |
| Operating Expenses | 1.63M | 2.63M | 5.50M |
| Operating Income | -1.09M | -2.51M | -4.97M |
| EBITDA | -121.58K | 16.80M | -7.27M |
| Interest Expense | 421.11K | 48.09K | 442.84K |
| Pretax Income | -542.68K | 16.75M | -7.72M |
| Tax Provision | -486.71K | 0 | 0 |
| Net Income | -108.24K | 16.82M | -7.67M |
| Diluted EPS | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 5.94M | 5.14M | 5.43M | 4.73M |
| Cost of Revenue | 4.41M | 3.45M | 3.61M | 3.77M |
| Gross Profit | 1.54M | 1.68M | 1.83M | 955.85K |
| Operating Expenses | 1.14M | 1.64M | 2.99M | 11.68M |
| Operating Income | 398.70K | 42.24K | -1.16M | -10.73M |
| EBITDA | 725.69K | 384.31K | 24.11K | 10.84M |
| Interest Expense | 77.76K | 46.18K | 778.66K | 616.42K |
| Pretax Income | 343.99K | 108.42K | -960.81K | 9.73M |
| Tax Provision | 208.14K | 0 | -486.71K | 0 |
| Net Income | 458.67K | 130.19K | -524.64K | 9.88M |
| Diluted EPS | 8,190.48 | 2,324.88 | -4,163.83 | 109.44 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 2.90M | 4.49M | 3.58M | 32.72M |
| Current Assets | - | 2.40M | 2.46M | 3.17M | 7.38M |
| Cash & Equivalents | - | 27.56K | 54.10K | 457.74K | 758.62K |
| Inventory | - | 46.91K | 126.26K | 80.81K | 335.36K |
| Receivables | - | 13.00K | 9.37K | 49.24K | 166.53K |
| Total Liabilities | - | 2.80M | 1.24M | 5.06M | 6.74M |
| Current Liabilities | - | 2.56M | 1.12M | 2.72M | 2.37M |
| Long Term Debt | - | - | - | 2.33M | 4.10M |
| Total Debt | - | 452.04K | 332.55K | 3.03M | 4.86M |
| Total Equity | - | 563.11K | 3.74M | -1.05M | 26.63M |
| Shares Outstanding | - | 56 | 126 | 126 | 80.28K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 1.71M | -1.77M | -8.26M | -10.93M |
| Investing Cash Flow | - | -94.45K | -69.85K | -53.05K | -7.56M |
| Financing Cash Flow | - | -1.63M | 1.88M | 8.68M | 18.99M |
| Capital Expenditure | - | -94.45K | -69.85K | -53.05K | -5.75M |
| Free Cash Flow | - | 1.62M | -1.84M | -8.32M | -16.68M |
| Net Change in Cash | - | -17.33K | 45.51K | 358.67K | 506.93K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 25.9% | 32.7% | 33.6% | 20.2% |
| Operating Margin % | 6.7% | 0.8% | -21.4% | -226.9% |
| Net Margin % | 7.7% | 2.5% | -9.7% | 209.0% |
| ROE % | 81.5% | 3.5% | 50.0% | 37.1% |
| ROCE % | 114.1% | 1.3% | -135.4% | -35.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | SBI Securities Co., Ltd. | - | 38 | $27 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NIVF
NewGenIvf Group Stock (NIVF) Opinions on Recent Insider Purchase - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOcjRraG90cXVxNVpMTnYtT2FWU3RBeGU2eV9yUEZpWkdyOGlrWkJuMW1XQngzVjQwR2JTemQyc0doSFUwTXo3VndPNnE1cjRtV3M0dmRhMUljR1BoenM0dmNJaVlXMW85eWlsVVhxMW5SOWJyaU1sSkxfV2F2MjZmbTh3RFREcE9xaFBfUk…
NIVF - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE8xMTJmTHBoYXlHVW9JbkhGcGlNRTV6cUIyVUgtSXhQX0lFUHJ4RkRDdkl2U3R4a3IxSWxvb3VwMldiNkhnYUE?oc=5" target="_blank">NIVF</a> <font color="#6f6f6f">Finviz</font>…
NIVF Stock Snaps Higher As Traders Focus On Volatility And Value - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPdDRGSFBCcnJpcFE3cDhZTjNsSHNUTWI4SVJReGRpYUQ3cXBiQzFvUlRtWFpJeDBVdm14WDFOZ3RmY1dESFZ1d1dfOFNDRkNMY2xRWXpDU2QyeEVyb2RDaW9qV2hVOUMyZjlsMFczWTBGdFdvcmJTZU1fekZVajRkSW1n?oc=5" target=…
NIVF Stock Slides After Volatile Spike Draws Trader Focus - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQME16Z0RQTWgxU0N2NDJaTTNVc0JPMFVwalhETFR3aGJobmplYWxiY2paSTZma0tnNnhoVlZrMTBteGJHUkRkZDAyMm9qRy1zN01Ic0RxdzBzckhLV3FBdW1EY0JNM1k0c3BZdC1VWEhPVEJubTZ2NnVxWjE2dmJJTzVBRQ?oc=5" targe…
Top movers in Friday's pre-market session - ChartMill
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOVmt4LWE5d0xqekpnMnYtb0FlNEg1ZUtQQ0c5bUdLVHRCLUhVZGVJcTQwdGhyNmc2TGlGUW5yQWZMZFdrenhvSC05THVGZENZTmhYeGhfVDk1R1Vlel83ZzF0N0ZGWVh0eGM4VmwxbVJTd2FFZEp4S3lPYVB5am94ai04OE84UXluYWxKdC…
Insider Stock Purchases: September 02, 2026 - Moomoo
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNNDRDVGhDdVNBMEkwMVVLZE41NzVwWU9xa2R5OVJrZm1xT0NwNmFyRFBrcDY2T2VzRGFJY3Q1djBNWTltTjBTUjc2X0cwYVFCQTRhYjhabGxUTUNxM3ZKX3JIQk9wVnBLWDg4dFlqSklDQzNHcmpJZGV2REI0WTgtdlhzMmhhdmdObzkw?o…
NIVF — Frequently Asked Questions
What is the current share price of NewGenIvf Group Limited (NIVF)?
As of 2026-09-19 21:16 PDT, NewGenIvf Group Limited (NIVF) trades at $1.11 on NasdaqCM. Its 52-week range is $1.11 to $1,122.66.
What is the market capitalisation of NIVF?
NewGenIvf Group Limited (NIVF) has a market capitalisation of $7.07M on NasdaqCM.
What is the return on equity (ROE) of NIVF?
NIVF has a return on equity (ROE) of 79.40%. Its return on capital employed (ROCE) is -35.34%.
Is NIVF a good stock to buy?
This page provides a data-driven analysis of NewGenIvf Group Limited (NIVF), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.